Your browser doesn't support javascript.
Testosterone in males with COVID-19: a 12-month cohort study.
Salonia, Andrea; Pontillo, Marina; Capogrosso, Paolo; Pozzi, Edoardo; Ferrara, Anna Maria; Cotelessa, Alice; Belladelli, Federico; Corsini, Christian; Gregori, Silvia; Rowe, Isaline; Carenzi, Cristina; Ramirez, Giuseppe A; Tresoldi, Cristina; Locatelli, Massimo; Cavalli, Giulio; Dagna, Lorenzo; Castagna, Antonella; Zangrillo, Alberto; Tresoldi, Moreno; Landoni, Giovanni; Rovere-Querini, Patrizia; Ciceri, Fabio; Montorsi, Francesco.
  • Salonia A; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.
  • Pontillo M; University Vita-Salute San Raffaele, Milan, Italy.
  • Capogrosso P; Laboratory Medicine Service, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Pozzi E; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.
  • Ferrara AM; Department of Urology and Andrology, Ospedale di Circolo and Macchi Foundation, Varese, Italy.
  • Cotelessa A; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.
  • Belladelli F; University Vita-Salute San Raffaele, Milan, Italy.
  • Corsini C; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.
  • Gregori S; Laboratory Medicine Service, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Rowe I; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.
  • Carenzi C; University Vita-Salute San Raffaele, Milan, Italy.
  • Ramirez GA; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.
  • Tresoldi C; University Vita-Salute San Raffaele, Milan, Italy.
  • Locatelli M; San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS Ospedale San Raffaele, Milan, Italy.
  • Cavalli G; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.
  • Dagna L; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.
  • Castagna A; University Vita-Salute San Raffaele, Milan, Italy.
  • Zangrillo A; Immunology, Rheumatology, Allergology and Rare Diseases Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Tresoldi M; Molecular Hematology Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Landoni G; Laboratory Medicine Service, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Rovere-Querini P; University Vita-Salute San Raffaele, Milan, Italy.
  • Ciceri F; Immunology, Rheumatology, Allergology and Rare Diseases Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Montorsi F; University Vita-Salute San Raffaele, Milan, Italy.
Andrology ; 2022 Oct 17.
Article in English | MEDLINE | ID: covidwho-2235183
ABSTRACT

BACKGROUND:

Male patients with COVID-19 have been found with reduced serum total testosterone (tT) levels and with more severe clinical outcomes.

OBJECTIVES:

To assess total testosterone (tT) levels and the probability of recovering eugonadal tT levels during a minimum 12-month timespan in a cohort of men who have been followed over time after the recovery from laboratory-confirmed COVID-19. MATERIALS AND

METHODS:

Demographic, clinical and hormonal values were collected for the overall cohort. Hypogonadism was defined as tT ≤9.2 nmol/l. The Charlson Comorbidity Index was used to score health-significant comorbidities. Descriptive statistics was used to compare hormonal levels at baseline versus 7-month (FU1) versus 12-month (FU2) follow-up, respectively. Multivariate cox proportional hazards regression model was used to identify the potential predictors of eugonadism recovery over time among patients with hypogonadism at the time of infection.

RESULTS:

Of the original cohort of 286 patients, follow-up data were available for 121 (42.3%) at FU1 and 63 (22%) patients at FU2, respectively. Higher median interquartile range (IQR) tT levels were detected at FU2 (13.8 (12.3-15.3) nmol/L) versus FU1 (10.2 [9.3-10.9] nmol/L) and versus baseline (3.6 [3.02-4.02] nmol/L) (all p < 0.0001), whilst both LH and E2 levels significantly decreased over the same time frame (all p ≤ 0.01). Circulating IL-6 levels further decreased at FU2 compared to FU1 levels (19.3 vs. 72.8 pg/ml) (p = 0.02). At multivariable cox regression analyses, baseline tT level (HR 1.19; p = 0.03 [1.02-1.4]) was independently associated with the probability of tT level normalization over time, after adjusting for potential confounders.

CONCLUSIONS:

Circulating tT levels keep increasing over time in men after COVID-19. Still, almost 30% of men who recovered from COVID-19 had low circulating T levels suggestive for a condition of hypogonadism at a minimum 12-month follow-up.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Andr.13322

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Year: 2022 Document Type: Article Affiliation country: Andr.13322